Major OEM to lab test Guident regenerative shock absorbers soon Watch Now

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.78
Ask: 0.82
Change: -0.02 (-2.44%)
Spread: 0.04 (5.13%)
Open: 0.82
High: 0.82
Low: 0.79
Yest. Close: 0.82
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.
Date   Source Headline
12th Mar 20197:00 amRNSSareum Holdings PLC Issue of Options
4th Mar 20197:00 amRNSHALF-YEARLY RESULTS ENDED 31 DECEMBER 2018
28th Feb 20192:04 pmRNSSierra Oncology has reported its 2018 Results
28th Feb 20198:14 amRNSNew SRA737 preclin data to be presented at AACR
23rd Jan 20191:38 pmRNSSierra Oncology to present SRA737 at DDR Tx Summit
18th Dec 201812:35 pmRNSResults of AGM
18th Dec 20187:00 amRNSAGM Statement
30th Nov 201811:17 amRNSAmendment to Preclinical Efficacy Announcement
30th Nov 20187:45 amRNSPreclinical Efficacy for Immunotherapy Combination
15th Nov 201810:24 amRNSPreclinical Data for SRA737 in Ovarian Cancer
14th Nov 20187:00 amRNSAGM NOTICE
13th Nov 20187:00 amRNSDirectorate Change
8th Nov 201812:28 pmRNSSierra Oncology Q3 2018 Results
26th Oct 20187:00 amRNSCompletion of Placing
1st Oct 20187:00 amRNSFINAL RESULTS FOR THE YEAR ENDED 30 JUNE 2018
27th Sep 20181:03 pmRNSNotice of Results
26th Sep 20187:00 amRNSTYK2/JAK1 selected for certain cancers
11th Sep 20187:00 amRNSPre-Close Trading Statement
10th Sep 20187:00 amRNSSelection of TYK2/JAK1 for autoimmune diseases
9th Aug 20181:15 pmRNSSareum notes Sierra Oncology Q2 2018 Results
11th Jul 20189:38 amRNSNotification of PCA Shareholding
15th Jun 20187:00 amRNSAdvisers
31st May 20187:00 amRNSSareum regains rights to Aurora+FLT3 inhibitors
10th May 201812:21 pmRNSSRA737 trial update in Sierra Oncology Q1 Results
24th Apr 20187:00 amRNSSareum to Present at BioTrinity 2018 in London
17th Apr 201812:45 pmRNSAACR 2018 Update
15th Mar 20187:00 amRNSLate-breaker abstract for SRA737 accepted for AACR
13th Mar 20187:00 amRNSInterim Results
27th Feb 201812:50 pmRNSSierra Oncology expands SRA737 development program
22nd Feb 20187:00 amRNSPreclinical synergy of sra737 and PARP inhibitor
13th Feb 20187:00 amRNSNotice of Interim Results
20th Dec 201711:00 amRNSIssue of Options
19th Dec 20177:00 amRNSPatent Grants in Japan & China for TYK2 Inhibitors
14th Dec 201711:01 amRNSResult of AGM
14th Dec 20177:00 amRNSAGM Statement
20th Nov 20177:00 amRNSNotice of AGM and Annual Report & Accounts
14th Nov 201712:05 pmRNSPlacing
31st Oct 20177:00 amRNSSierra Reports Preclinical Data for Chk1 Inhibitor
19th Oct 20177:00 amRNSFinal Results
9th Oct 201712:00 pmRNSSierra Oncology host KOL Meeting on 12 Oct in NY
18th Sep 201712:00 pmRNSSierra Oncology to host call on Chk1 inhibitor
22nd Aug 20177:00 amRNSPre-Close Trading Statement
19th Jun 20177:00 amRNSSareum to Present at the ICCS 2017
5th Jun 201712:13 pmRNSChk1 Clinical Trials Update
31st May 20177:00 amRNSSierra Oncology Granted US and EU Patents
25th May 20177:00 amRNSSierra Oncology to Present at ASCO Annual Meeting
9th May 20177:00 amRNSSareum to Present at BioTrinity 2017
9th Mar 20177:00 amRNSDirector Shareholding
20th Feb 20177:00 amRNSHalf-year Results
9th Feb 20177:00 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.